Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection

A long-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is currently in clinical development for PrEP. Although the long plasma half-life of CAB-LA is an important attribute for PrEP, it also raises concerns about drug resistance emergence if someone becomes infecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Radzio-Basu, Jessica, Council, Olivia, Cong, Mian-er, Ruone, Susan, Newton, Alicia, Wei, Xierong, Mitchell, James, Ellis, Shanon, Petropoulos, Christos J., Huang, Wei, Spreen, William, Heneine, Walid, García-Lerma, J. Gerardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494879/
https://www.ncbi.nlm.nih.gov/pubmed/31043606
http://dx.doi.org/10.1038/s41467-019-10047-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494879/
https://www.ncbi.nlm.nih.gov/pubmed/31043606
http://dx.doi.org/10.1038/s41467-019-10047-w

Ejemplares similares